GoAI
Get started
Kontafarma China Holdings Ltd logo

Kontafarma China Holdings Ltd

1312.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

HK$0.029

−HK$0.003 · -9.37%

Aug 24, 11:15 AM HKT

1312.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Kontafarma China Holdings Ltd. directs its business efforts through two principal segments: Pharmaceutical and Fitness. Its Pharmaceutical arm is responsible for the manufacturing and marketing of prescription medications and associated laboratory goods. Meanwhile, the Fitness division oversees the management of health clubs, delivers advisory services for physical well-being and health-related pursuits, and runs a franchise model to generate royalty revenue. Established on March 21, 2011, the company maintains its corporate headquarters in Hong Kong.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
HK
CEO
Feifei Wang
Listed since
Jan 18, 2012
Employees
636

Market position

Day range

Current HK$0.029

52-week range

Current HK$0.029

Open
HK$0.032
Previous close
HK$0.032
Volume
42K
0.02× average
Average volume
2.13M
Average daily volume
Market cap
161.78M HKD
Beta
-0.02
Market reference 1
50-day average
HK$0.0293
-1.16% below average
200-day average
HK$0.0294
-1.46% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
299.4M HKD
P/E (TTM)
-0.38×
P/B (TTM)
0.29×
P/S (TTM)
0.18×
EV / EBITDA
-1.95×
Earnings yield
-264.46%
Free cash flow yield
32.85%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
56.15%
Operating margin
-22.50%
Net margin
-46.77%
Return on equity
-77.33%
Return on assets
-40.17%
Return on invested capital
-33.21%

Financial health

Debt / equity
0.37×
Current ratio
0.79×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends69%27%-15%-57%Gross margin, FY2021: 49.32%Gross margin, FY2022: 56.62%Gross margin, FY2023: 58.25%Gross margin, FY2024: 57.51%Gross margin, FY2025: 56.15%Operating margin, FY2021: -12.16%Operating margin, FY2022: -15.36%Operating margin, FY2023: -20.31%Operating margin, FY2024: -4.74%Operating margin, FY2025: -26.55%Net margin, FY2021: -1.87%Net margin, FY2022: -4.65%Net margin, FY2023: -3.56%Net margin, FY2024: -8.42%Net margin, FY2025: -46.77%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 49.32%. Gross margin FY2022 56.62%. Gross margin FY2023 58.25%. Gross margin FY2024 57.51%. Gross margin FY2025 56.15%. Operating margin FY2021 -12.16%. Operating margin FY2022 -15.36%. Operating margin FY2023 -20.31%. Operating margin FY2024 -4.74%. Operating margin FY2025 -26.55%. Net margin FY2021 -1.87%. Net margin FY2022 -4.65%. Net margin FY2023 -3.56%. Net margin FY2024 -8.42%. Net margin FY2025 -46.77%.

Income trends

Revenue

914.71M HKD+1.92%

Operating income

−242.83M HKD-471.17%

Net income

−427.85M HKD-466.41%
Income trends across reported periods1.05B HKD511.94M HKD−25.08M HKD−562.1M HKDRevenue, FY2021: 803.27M HKDRevenue, FY2022: 894.06M HKDRevenue, FY2023: 809.11M HKDRevenue, FY2024: 897.52M HKDRevenue, FY2025: 914.71M HKDOperating income, FY2021: −97.71M HKDOperating income, FY2022: −137.29M HKDOperating income, FY2023: −164.3M HKDOperating income, FY2024: −42.51M HKDOperating income, FY2025: −242.83M HKDNet income, FY2021: −15.05M HKDNet income, FY2022: −41.55M HKDNet income, FY2023: −28.84M HKDNet income, FY2024: −75.54M HKDNet income, FY2025: −427.85M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 803.27M HKD. Revenue FY2022 894.06M HKD. Revenue FY2023 809.11M HKD. Revenue FY2024 897.52M HKD. Revenue FY2025 914.71M HKD. Operating income FY2021 −97.71M HKD. Operating income FY2022 −137.29M HKD. Operating income FY2023 −164.3M HKD. Operating income FY2024 −42.51M HKD. Operating income FY2025 −242.83M HKD. Net income FY2021 −15.05M HKD. Net income FY2022 −41.55M HKD. Net income FY2023 −28.84M HKD. Net income FY2024 −75.54M HKD. Net income FY2025 −427.85M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue914.71M HKD897.52M HKD809.11M HKD894.06M HKD803.27M HKD
Cost of goods sold401.07M HKD381.36M HKD337.82M HKD387.84M HKD478.2M HKD
Gross profit513.64M HKD516.16M HKD471.29M HKD506.22M HKD396.18M HKD
Research and development8.37M HKD34.63M HKD20.75M HKD29.11M HKD45.63M HKD
Selling, general, and administrative550.17M HKD524.04M HKD542.49M HKD605.76M HKD489.23M HKD
Operating expenses558.53M HKD558.67M HKD563.62M HKD590.63M HKD502.98M HKD
Interest income1.99M HKD5.82M HKD3.5M HKD5.18M HKD3.31M HKD
Interest expense10.76M HKD13.39M HKD15.25M HKD23.28M HKD33.61M HKD
Depreciation and amortization89.3M HKD42.49M HKD107.16M HKD121.39M HKD133.03M HKD
Operating income−242.83M HKD−42.51M HKD−164.3M HKD−137.29M HKD−97.71M HKD
Net income−427.85M HKD−75.54M HKD−28.84M HKD−41.55M HKD−15.05M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.05

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.050-0.04-0.09Q4 '21Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25Q3 '25
Q4 2021, reported Dec 31, 2021: actual 0.011, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 29, 2022: actual -0.006, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 25, 2023: actual -0.002, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 30, 2023: actual 0.007, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 28, 2024: actual -0.012, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 28, 2024: actual 0.001, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual -0.014, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 1, 2025: actual -0.051, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates523.01M468.1M413.2M358.29MQ4 '21Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25Q3 '25
Q4 2021, reported Dec 31, 2021: actual 502.9M HKD, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 29, 2022: actual 451.09M HKD, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 25, 2023: actual 442.98M HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 30, 2023: actual 430.71M HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 28, 2024: actual 378.4M HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 28, 2024: actual 458.52M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 28, 2025: actual 439M HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 1, 2025: actual 452.72M HKD, estimate —, surprise —, Comparison unavailable.

1312.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.30

-3.94%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.8

-2.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.54

-4.82%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.14

-5.86%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.5

-1.86%

Continue in GoAI

Research 1312.HK

research.disclaimer